Skip to main content
NewslettersWatchlist
Introducing The Globe and Mail Trade Off — A Free Stock-Picking Contest With $10,000 in Cash Prizes. Enter Now!

Oncolytics Bio(ONC-T)
TSX

Today's Change
Real-Time Last Update
Day Low1.39
Day High1.44
Open:1.42
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

TOP STORIES: Oncolytics Bio

Select a category then submit the form to load news
Newswire.ca
Biotech Stocks Rally as Oncology Market Targets $866B by 2034
Newswire.ca
Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment
BayStreet.ca
FDA Fast-Track Cancer Treatments Drive $900B Market Growth Forecast
Baystreet
Stocks in play: Oncolytics Biotech Inc
Newswire.ca
Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders
Baystreet
Stocks in play: Oncolytics Biotech Inc
Newswire.ca
Oncolytics Biotech® Reports Second Quarter Financial Results and Details Clinical Program Plans for Pelareorep
Newswire.ca
Oncolytics Biotech® Announces Voluntary Delisting from the Toronto Stock Exchange
Newswire.ca
Oncolytics Biotech® Announces Upcoming Annual General Meeting and Second Quarter Financial Results
Newswire.ca
Biotech Underdogs Line Up for Pivotal Shots at Game-Changing Cancer Treatments
BayStreet.ca
Survival Data and Regulatory Greenlights Fuel Momentum in Immunotherapy Stocks
Baystreet
Stocks in play: Oncolytics Biotech Inc
Newswire.ca
Oncolytics Biotech® to Engage FDA for Potential Registration-Enabled Study in First-Line Pancreatic Cancer with Goal to Launch Trial Activities by Year-End
Newswire.ca
Key Opinion Leader Event Highlights Pelareorep's Compelling Pancreatic and Gastrointestinal Data And Future Potential
BayStreet.ca
Cancer Surge Meets Funding Crunch as Breakthrough Biotechs Line Up Milestones in 2025
Newswire.ca
High‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds
Newswire.ca
Oncolytics Biotech® Regains Compliance with Nasdaq Trading Rules
Newswire.ca
Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities
BayStreet.ca
Emerging Oncology Breakthroughs Signal Opportunity Despite Research Funding Crunch
Baystreet
Stocks in play: Oncolytics Biotech Inc
Newswire.ca
Oncolytics Biotech® Presents Aggregated Translational Data Providing Evidence of Pelareorep's Effectiveness Across Multiple Tumor Types
Baystreet
Stocks in play: Oncolytics Biotech Inc
BayStreet.ca
Next-Gen Cancer Treatments Gain Steam Amid Oncology Industry Shakeups
PR Newswire
Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up
PR Newswire
Oncolytics Biotech® to Host Key Opinion Leader Discussion Focusing on Pancreatic and Gastrointestinal Cancers
Newswire.ca
Amid NCI Budget Fears, Emerging Oncology Stocks Gain Attention
BayStreet.ca
Investors Turn to Cancer Breakthroughs as Federal Funding Faces Deep Cuts
Baystreet
Stocks in play: Oncolytics Biotech Inc
GlobeNewswire
Global Oncology Breakthroughs Being Fueled by Advancements in Clinical Trials and New Therapies
PR Newswire
Oncolytics Biotech® Highlights Transformative Pelareorep Survival Data in Multiple Tumors and Commitment to Registration-Enabling Studies
Baystreet
Stocks in play: Oncolytics Biotech Inc.
Newswire.ca
Oncology Innovation Just Hit a Turning Point -- Here's What to Watch

Profile

Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2025.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2025 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.